SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinomaJorien B.E. Janssen, Henk M.W. Verheul|The Oncologist|2025Cited by 0